Johnson & Johnson

Early data released form phase one and two trials of Johnson & Johnson’s COVID-19 vaccine show that it appears to be safe and generates an immune response

The scientific leader of the U.S. vaccine effort will stay in the role for 30 days, but won’t be chief advisor as of Inauguration Day, sources say.

Many people have questions about the level of protection after receiving the first dose of a COVID-19 vaccination. A Massachusetts scientist who developed the Johnson & Johnson vaccine discusses those protection levels, how long you should still wear mask and a strategy shift to reach herd immunity.

Many people have questions about the level of protection after receiving the first dose of a COVID-19 vaccination. A Massachusetts scientist who developed the Johnson & Johnson vaccine discusses those protection levels, how long you should still wear mask and a strategy shift to reach herd immunity.

A one-shot vaccine could significantly improve our ability to fight the virus — and we may have one soon.

CNBC’s Jim Cramer called the recently approved coronavirus stimulus package “the $900 billion bridge” to a widely available Covid vaccine.

Two COVID-19 vaccines have now been approved for emergency use by the U.S. Food and Drug Administration as the nation continues to see record numbers of coronavirus cases. In the midst of all the news from Pfizer and Moderna, though, another company has announced it made progress in its own vaccine trials. Johnson & Johnson took a big step...

Johnson & Johnson took a big step forward this week as they announced their phase 3 trials are now fully enrolled with 45,000 people.

“This has been a challenging process because there have been multiple conversations happening as recently as November,” Dr. Scott Gottlieb told CNBC.

Bill Gates has predicted there could be as many as half a dozen Covid-19 vaccines approved and ready for distribution by the first quarter next year.

“It reminded me of getting the flu shot. It was virtually painless, the vaccine itself,” Republican Sen. Steve Daines of Montana told CNBC.

Vaccine news this week has failed to give the health-care sector a lift. Mark Newton of Newton Advisors shares three charts that put the move into context.

“The reason I participated in this trial was because I think the vaccines are so important,” Ohio Republican Sen. Rob Portman told CNBC on Tuesday.

U.S. stocks jumped, nearing a record 30,000 on the Dow, after Moderna said preliminary trial data showed its coronavirus vaccine is more than 94% effective.

Emirates said it was working with Pfizer on the complex logistics of transporting its vaccine to the world.

AstraZeneca and Johnson & Johnson announced Friday that they would resume their phase 3 clinical trials on COVID-19 vaccine candidates in the U.S, NBC News reports.

A participant in Johnson & Johnson’s COVID-19 vaccine trial got ill, leading to a pause.

Just weeks after announcing COVID-19 vaccines were in the final stages, Johnson & Johnson has announced it is pausing its clinical trials.

A late-stage study of Johnson & Johnson’s COVID-19 vaccine candidate has been paused while the company investigates whether a study participant’s “unexplained illness” is related to the shot. The company said in a statement Monday evening that illnesses, accidents and other so-called adverse events “are an expected part of any clinical study, especially large studies,” but that its physicians...

A late-stage study of Johnson & Johnson’s COVID-19 vaccine candidate has been paused while the company investigates whether a study participant’s “unexplained illness” is related to the shot.